• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.慢性肾病患者继发性甲状旁腺功能亢进的相关危险因素。
Exp Ther Med. 2016 Aug;12(2):1206-1212. doi: 10.3892/etm.2016.3438. Epub 2016 Jun 8.
2
Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study.终末期肾病中相关继发性甲状旁腺功能亢进与血清成纤维细胞生长因子-23的关系:一项病例对照研究
Indian J Endocrinol Metab. 2011 Apr;15(2):105-9. doi: 10.4103/2230-8210.81939.
3
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
4
Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.依特卡塞肽(AMG 416),一种钙敏感受体的肽类激动剂,可维持已患有继发性甲状旁腺功能亢进的肾部分切除大鼠的皮质骨结构和骨强度。
Bone. 2017 Dec;105:163-172. doi: 10.1016/j.bone.2017.08.026. Epub 2017 Sep 1.
5
Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.老年慢性肾脏病患者发生甲状旁腺功能亢进的风险更高。
Int Urol Nephrol. 2017 Oct;49(10):1815-1821. doi: 10.1007/s11255-017-1650-7. Epub 2017 Jul 10.
6
Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels.Pin1与慢性肾脏病继发性甲状旁腺功能亢进:基因多态性与蛋白水平
Ren Fail. 2017 Nov;39(1):159-165. doi: 10.1080/0886022X.2016.1256310. Epub 2016 Nov 23.
7
Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.低剂量阿法骨化醇控制透析前慢性肾脏病的继发性甲状旁腺功能亢进症。
Nephron Clin Pract. 2010;114(4):c268-76. doi: 10.1159/000276579. Epub 2010 Jan 20.
8
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).慢性肾脏病3期和4期患者的血浆甲状旁腺激素水平与心血管疾病患病率:来自肾脏早期评估项目(KEEP)的分析
Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S3-10. doi: 10.1053/j.ajkd.2008.11.029.
9
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.盐酸西那卡塞:一种治疗慢性肾脏病所致继发性甲状旁腺功能亢进的新疗法。
J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010.
10
[Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area].[雷克雅未克地区成年人群继发性甲状旁腺功能亢进(SHPT)的患病率及病因]
Laeknabladid. 2005 Feb;91(2):161-9.

引用本文的文献

1
Parathyroid Hormone Concentration in Dogs Affected by Acute Kidney Injury Compared with Healthy and Chronic Kidney Disease.与健康犬和患有慢性肾病的犬相比,急性肾损伤犬的甲状旁腺激素浓度
Vet Sci. 2025 Feb 6;12(2):131. doi: 10.3390/vetsci12020131.
2
A Nomogram for Predicting Secondary Hyperparathyroidism after Bariatric Surgery: A Retrospective Study on Short-Term Outcome.一种用于预测减肥手术后继发性甲状旁腺功能亢进的列线图:短期结果的回顾性研究
Obes Surg. 2025 Jan;35(1):206-215. doi: 10.1007/s11695-024-07623-5. Epub 2024 Dec 20.
3
Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.估算慢性肾脏病患者继发性甲状旁腺功能亢进症的全球患病率。
Front Endocrinol (Lausanne). 2024 Jun 21;15:1400891. doi: 10.3389/fendo.2024.1400891. eCollection 2024.
4
Full thermal ablation versus partial thermal ablation for secondary hyperparathyroidism: A meta-analysis.全甲状腺消融与部分甲状腺消融治疗继发性甲状旁腺功能亢进症的疗效比较:一项荟萃分析。
Medicine (Baltimore). 2023 Dec 1;102(48):e36422. doi: 10.1097/MD.0000000000036422.
5
Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease.慢性肾脏病成人患者的继发性甲状旁腺功能亢进与不良健康结局
Clin Kidney J. 2021 Jan 20;14(10):2213-2220. doi: 10.1093/ckj/sfab006. eCollection 2021 Oct.
6
Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis.帕立骨化醇与西那卡塞治疗慢性肾脏病继发性甲状旁腺功能亢进的Meta分析
Exp Ther Med. 2020 Oct;20(4):3237-3243. doi: 10.3892/etm.2020.9044. Epub 2020 Jul 24.
7
Evaluation of renal osteodystrophy in the dental clinic by assessment of mandibular and phalangeal cortical indices.通过评估下颌骨和指骨皮质指数在牙科诊所评估肾性骨营养不良。
Oral Radiol. 2018 May;34(2):172-178. doi: 10.1007/s11282-017-0302-z. Epub 2017 Sep 4.

本文引用的文献

1
Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis.慢性肾脏病发生和进展的危险因素:一项系统评价与探索性Meta分析
Medicine (Baltimore). 2016 Mar;95(11):e3013. doi: 10.1097/MD.0000000000003013.
2
Correlates of parathyroid hormone concentration in hemodialysis patients.血液透析患者甲状旁腺激素浓度的相关因素。
Nephrol Dial Transplant. 2013 Jun;28(6):1516-25. doi: 10.1093/ndt/gfs598. Epub 2013 Jan 24.
3
Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options.代谢性酸中毒与慢性肾脏病进展:发病机制、发病机制及治疗选择。
Nefrologia. 2012;32(6):724-30. doi: 10.3265/Nefrologia.pre2012.Jul.11515.
4
Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD?代谢性酸中毒与肾脏疾病:碳酸氢盐治疗能否减缓 CKD 的进展?
Nephrol Dial Transplant. 2012 Aug;27(8):3056-62. doi: 10.1093/ndt/gfs291.
5
Inflammation markers, chronic kidney disease, and renal replacement therapy.炎症标志物、慢性肾脏病与肾脏替代治疗。
Adv Perit Dial. 2011;27:33-7.
6
Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?甲状旁腺激素、维生素 D、肾功能障碍和心血管疾病:是依赖还是独立的危险因素?
Am Heart J. 2011 Aug;162(2):331-339.e2. doi: 10.1016/j.ahj.2011.05.005.
7
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.继发性甲状旁腺功能亢进:发病机制、疾病进展和治疗选择。
Clin J Am Soc Nephrol. 2011 Apr;6(4):913-21. doi: 10.2215/CJN.06040710. Epub 2011 Mar 31.
8
The roles of the skeleton and phosphorus in the CKD mineral bone disorder.骨骼和磷在 CKD 矿物质骨代谢紊乱中的作用。
Adv Chronic Kidney Dis. 2011 Mar;18(2):98-104. doi: 10.1053/j.ackd.2011.01.001.
9
Renal lipid metabolism and lipotoxicity.肾脏脂质代谢与脂毒性
Curr Opin Nephrol Hypertens. 2010 Jul;19(4):393-402. doi: 10.1097/MNH.0b013e32833aa4ac.
10
Risk factors for progression of chronic kidney disease.慢性肾脏病进展的危险因素。
Curr Opin Pediatr. 2010 Apr;22(2):161-9. doi: 10.1097/MOP.0b013e328336ebb0.

慢性肾病患者继发性甲状旁腺功能亢进的相关危险因素。

Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.

作者信息

Wei Yudan, Lin Jing, Yang Fan, Li Xiujiang, Hou Yue, Lu Ronghua, Shi Xiaonv, Liu Zhi, Du Yujun

机构信息

Department of Nephrology, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Department of Nephrology, The First Affiliated Hospital of Luohe Medical College, Luohe, Henan 462000, P.R. China.

出版信息

Exp Ther Med. 2016 Aug;12(2):1206-1212. doi: 10.3892/etm.2016.3438. Epub 2016 Jun 8.

DOI:10.3892/etm.2016.3438
PMID:27446345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4950648/
Abstract

Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD), and its development and progression are affected by various factors. The aim of the present study was to identify the risk factors for SHPT in patients with CKD. A retrospective study was performed in 498 patients (305 males and 193 females) with CKD, observed in the The First Hospital of Jilin University between January 2008 and December 2012. The demographic, clinical and laboratory data were collected. Patients were divided into the SHPT group (n=424) with elevated serum parathyroid hormone (PTH) expression levels and the control group (n=74) with normal serum PTH expression levels. Univariate and multivariate regression analyses were employed to explore the risk factors for SHPT. Serum PTH expression levels in women with CKD were significantly higher than in men (P=0.047). Serum PTH expression levels were positively correlated with the expression levels of serum creatinine (P<0.01), phosphorus (P<0.01), C-reactive protein (P<0.05), triglyceride (P<0.05), cholesterol (P<0.05) and low-density lipoprotein cholesterol (P<0.05), but were negatively correlated with the expression levels of hemoglobin (P<0.05), calcium (P<0.01) and CO combining power (P<0.01) in patients with CKD. Multivariate analysis showed that the serum expression levels of creatinine [µmol/l; odds radio (OR), 1.003; 95% confidence interval (CI), 1.002-1.004; P=0.001] and phosphorus (mmol/l; OR, 2.19; 95% CI, 1.254-3.826; P=0.006) in patients with CKD significantly influenced serum PTH expression levels. The SHPT risk factors include female gender, low calcium, high phosphorus, acidosis, anemia, hypertension, hyperlipidemia and micro-inflammation, with blood phosphorus and creatinine being independent risk factors.

摘要

继发性甲状旁腺功能亢进(SHPT)在慢性肾脏病(CKD)患者中很常见,其发生和进展受多种因素影响。本研究的目的是确定CKD患者发生SHPT的危险因素。对2008年1月至2012年12月期间在吉林大学第一医院观察的498例CKD患者(305例男性和193例女性)进行了一项回顾性研究。收集了人口统计学、临床和实验室数据。患者被分为血清甲状旁腺激素(PTH)表达水平升高的SHPT组(n = 424)和血清PTH表达水平正常的对照组(n = 74)。采用单因素和多因素回归分析来探讨SHPT的危险因素。CKD女性患者的血清PTH表达水平显著高于男性(P = 0.047)。CKD患者的血清PTH表达水平与血清肌酐(P < 0.01)、磷(P < 0.01)、C反应蛋白(P < 0.05)、甘油三酯(P < 0.05)、胆固醇(P < 0.05)和低密度脂蛋白胆固醇(P < 0.05)的表达水平呈正相关,但与血红蛋白(P < 0.05)、钙(P < 0.01)和CO结合力(P < 第1页,共2页0.01)的表达水平呈负相关。多因素分析表明,CKD患者的血清肌酐表达水平[µmol/l;比值比(OR),1.003;95%置信区间(CI),1.002 - 1.004;P = 0.001]和磷(mmol/l;OR,2.19;95%CI,1.254 - 3.826;P = 0.006)显著影响血清PTH表达水平。SHPT的危险因素包括女性、低钙、高磷、酸中毒、贫血、高血压、高脂血症和微炎症,血磷和肌酐是独立危险因素。